Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 41Genitourinary 25Thoracic 20Gynecologic 15Lymphoid 11Head & Neck 10Breast 9Sarcoma 5Other solid neoplasm 2Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1CNS 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 17Biopsy 16Magnetic Resonance Spectroscopy 10pembrolizumab 9Paclitaxel 6atezolizumab 5Standard of Care 5Bevacizumab 5trastuzumab deruxtecan 3ipatasertib 3durvalumab 3X-Rays 3Taxes 3Radiotherapy 3Exercise 3Cetuximab 3Carboplatin 3Capecitabine 3nilotinib 2inavolisib 2dostarlimab 2cabozantinib 2Tiragolumab 2Radiosurgery 2Radiation 2Practice Guidelines as Topic 2Pemetrexed 2Oxaliplatin 2Nivolumab 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gemcitabine × Tumor-Agnostic × 30 days × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡